Establishment and Characterization of Three GEP-NEC Cell Lines for In Vitro and In Vivo Studies Abstract #1551

Introduction: To date chemotherapeutic concepts applying cisplatin/etoposide for the treatment of highly aggressive GEP-NEC do not provide convincing results. Thus, there is an urgent need for NEC cell line models that provide a reliable experimental system in identifying novel therapeutic targets.
Aim(s): Three NEC cell lines were established from a liver metastasis, a lymph node metastasis and an inguinal metastasis from patients with large cell NEC arising from the gastroesophageal junction, colon and anal canal, respectively.
Materials and methods: Neuroendocrine markers were analyzed by using RT-PCR and immunohistochemistry. Authenticity of the cell lines was verified by DNA fingerprinting and array CGH. In vivo tumorigenicity was evaluated in a mouse model and sensitivity against chemotherapeutic agents was assessed in vitro.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Andreas Krieg
Keywords: GEP-NEC

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1545 In Vivo Expression of Survivin and XIAP in Medullary Thyroid Carcimoma
Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5 % of all thyroid malignancies. Although surgery remains the first line therapy with curative intention, for advanced MTC current chemotherapeutic regimes do not provide promising results. Consequently, the identification of biologically relevant biomarkers that are associated with MTC progression may provide novel therapeutic targets.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr. Andreas Krieg
Keywords: MTC, IAP, survivin, XIAP
#2257 Poorly Differentiated Neuroendocrine Carcinomas of the Colon: A Clinicopathological Study
Introduction: Neuroendocrine carcinomas (NEC) of the colon and rectum are aggressive and rare tumours. The Digestive Tract WHO classification 2010 defines the entity of large cell NEC (LCNEC) in contrast to small cell NEC (SCNEC).
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Inga Boeck
Authors: Boeck I, Weihe E, Krieg A, Gabbert H E, ...
#1781 Clinical Characteristics and Treatment Outcome of Advanced G3 Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)- A Retrospective Analysis
Introduction: Advanced poorly differentiated GEP-NEC are uncommon neoplasms and treated mainly with platinum-based chemotherapy associated with etoposide.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Raluca Roxana Grigorescu
#1102 First-Line Chemotherapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): A Retrospective Analysis
Introduction: Gastroenteropancreatic neuroendocrine neoplasia (GEP-NENs) are divided on the basis of Ki67 status into G1-G2 neuroendocrine tumors (NETs) (Ki67 <20%) and neuroendocrine carcinoma (NECs) (Ki67 >20% ). NEC patients generally have a poor prognosis and the first choice treatment is chemotherapy.A cisplatin/etoposide combination is often used as NECs are considered clinically similar to small cell lung cancer (SCLC), but no literature data is available. There is some evidence to suggest that carboplatin may also be effective in metastatic SCLC.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Alberto Bongiovanni
Keywords: GEP-NEC, chemotherapy
#1204 Clinico-Pathologic and Survival Analysis of 211 GastroEnteroPancreatic G3 Neuroendocrine Carcinomas (GEP-NECs)
Introduction: GEP-NECs show Ki67>20% and/or >20 mitoses x10 HPF. Mixed AdenoNeuroendocrine Carcinomas (MANECs) are mixed exocrine-neuroendocrine neoplasms. NECs are associated with poor prognosis but recent findings have suggested that there is a fraction of patients showing a better than expected survival rate.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
Keywords: NEC, Ki67, MANEC, PROGNOSIS